gip glp-1 dual agonist GIPR/GLP-1R therapies for diabetes and weight loss—chemistry, physiology, and clinical applications Targeting GLP-1, GIP & GCG

Accordingly, a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) represents a contraindication to the use of GLP-1RAs and are exclusion criteria for participation in clinical trials with GLP-1RAs

John Van Geest Centre for Brain Repair, Department of Clinical Neurosciences

Experts believe that as the popularity of Ozempic and other GLP-1 agonists continues to grow, so will the number of people who report adverse gastrointestinal events such as gastroparesis

2024;10(2):e143

Glucagon-like peptide 1 induces pancreatic -cell proliferation Via transactivation of the epidermal growth factor receptor